Cencora, Inc. (COR)
Are Medical Stocks Lagging Cencora, Inc. (COR) This Year?
Here is how Cencora (COR) and Halozyme Therapeutics (HALO) have performed compared to their sector so far this year.
Here's Why Cencora (COR) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Cencora, Inc. (COR) Hits Fresh High: Is There Still Room to Run?
Cencora (COR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Why Cencora (COR) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Cencora Q4 Earnings & Revenues Beat Estimates, Margins Decline Y/Y
COR's fourth-quarter fiscal 2024 results showcase a strong segmental performance.
Cencora Acquires Retina Care Practice Network For $4.6 Billion, Boosts Dividend On Better Than Expected Q4 Earnings
On Wednesday, Cencora, Inc.'s COR fourth-quarter 2024 sales increased 14.7% to $79.1 billion, beating the consensus of $77.65 billion.
Cencora, Inc. (COR) Q4 2024 Earnings Call Transcript
Cencora, Inc. (NYSE:COR ) Q4 2024 Earnings Call Transcript November 6, 2024 8:30 AM ET Company Participants Bennett Murphy - SVP, Head of IR Bob Mauch - President and CEO Laz Krikorian - SVP and CAO Conference Call Participants Lisa Gill - JPMorgan Michael Cherny - Leerink Partners Elizabeth Anderson - Evercore ISI George Hill - Deutsche Bank Eric Percher - Nephron Research Stephanie Davis - Barclays Kevin Caliendo - UBS Eric Coldwell - Baird Erin Wright - Morgan Stanley Allen Lutz - Bank of America Charles Rhyee - TD Cowen Operator Hello, everyone, and welcome to today's Cencora Q4 Full Year 2024 Earnings Call. My name is Drew, and I'll be the operator today.
Here's Why Cencora (COR) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Cencora (COR) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Cencora (COR) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Cencora (COR) Tops Q4 Earnings and Revenue Estimates
Cencora (COR) came out with quarterly earnings of $3.34 per share, beating the Zacks Consensus Estimate of $3.21 per share. This compares to earnings of $2.86 per share a year ago.
Cencora to buy Retina Consultants of America for $4.6 bln
Drug distributor Cencora said on Wednesday it would acquire Retina Consultants of America (RCA) for $4.6 billion in cash, gaining access to its network of eye specialists.
Cencora to Report Q4 Earnings: What's in Store for the Stock?
COR's fiscal fourth-quarter results are likely to reflect decent U.S. Healthcare Solutions segmental performance.
